Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: Role of anti-inflammation effects

American Journal of Nephrology

Volumn 29, Issue 5, 2009, Pages 392-397

  Chiang, Chih Kang ^a,b,c   Yang, Shao Yu ^a,c   Peng, Yu Sen ^c   Hsu, Shih Ping ^c   Pai, Mei Fen ^c   Huang, Jen Wen ^a   Hung, Kuan Yu ^a,b,c   Wu, Kuan Dun ^a  

^a Departments of Internal Medicine   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Dialysis; Erythropoietin stimulating agent; Inflammation; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; ERYTHROPOIETIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 18; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ACNE; ADJUVANT THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HEMATOCRIT; HEMODIALYSIS PATIENT; HUMAN; LOW DRUG DOSE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANEMIA; DRUG SYNERGISM; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RENAL DIALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54949085025     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000169658     Document Type: Article

References (31)

1. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B: High-dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13:1206-1210.
2. Erturk S, Nergizoglu G, Ates K, Duman N, Erbay B, Karatan O, Ertug AE: The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant 1999; 14:1912-1916.
3. Ifudu O, Feldman J, Friedman EA: The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996;334:420-425.
4. Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fi-brosis on the response to erythropoietin in uremia. N Engl J Med 1993;328:171-175.
5. Acaray A, Pinar R: Quality of life in Turkish haemodialysis patients. Int Urol Nephrol 2005;37:595-602.
6. Chiang CK, Peng YS, Chiang SS, Yang CS, He YH, Hung K Y, Wu KD, Wu MS, Fang CC, Tsai TJ, Chen WY: Health-related quality of life of hemodialysis patients in Taiwan: a multicenter study. Blood Purif 2004;22:490-498.
7. Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S: Long-term study of high-co-morbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis 2003;42:1020-1035.
8. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL: Interleu-kin-6 predicts hypoalbuminemia, hypocho-lesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107-114.
9. Chiang CK, Hsu SP, Pai MF, Peng YS, Ho TI, Liu SH, Hung KY, Tsai TJ: Interleukin-18 is a strong predictor of hospitalization in haemodialysis patients. Nephrol Dial Transplant 2004; 19:2810-2815.
10. Honda H, Qureshi AR, Heimburger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B: Serum albumin, C-reactive protein, interleukin-6, and fetuin as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006;47:139-148.
11. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD: Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004;80:299-307.
12. Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS: Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005;45:324-333.
13. Wanner C, Metzger T: C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002;17(suppl 8):29-32.
14. Zoccali C, Tripepi G, Mallamaci F: Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol 2006; 17: S169-S173.
15. Stenvinkel P: The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 2001; 16(suppl 7):36-40.
16. Sirken G, Kung SC, Raja R: Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J 2003;49:422-425.
17. Chen LP, Chiang CK, Chan CP, Hung KY, Huang CS: Does periodontitis reflect inflammation and malnutrition status in hemodialysis patients? Am J Kidney Dis 2006; 47:815-822.
18. Chiang CK, Hsu SP, Pai MF, Peng YS, Ho TI, Liu SH, Hung KY, Tsai TJ, Hsieh BS: Plasma interleukin-18 levels in chronic renal failure and continuous ambulatory peritoneal dialysis. Blood Purif 2005;23:144-148.
19. Chiang CK, Huang JW, Hsu SP, Ho TI, Pai MF, Peng YS, Liu SH, Hung KY, Tsai TJ: Plasma interleukin-18 levels in hemodialysis patients: increased by dialysis process and association with interleukin-6 and tumor necrotic factor-a. Blood Purif 2006;24:174-179.
20. Ikejiri A, Hirano T, Murayama S, Yoshino G, Gushiken N, Hyodo T, Taira T, Adachi M: Effects of atorvastatin on triglyceride-rich li-poproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 2004;53:1113-1117.
21. Macdougall IC: Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int 2001;78:S67-S72.
22. Means RT Jr, Krantz SB: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80:1639-1647.
23. Schooley JC, Kullgren B, Allison AC: Inhibition by interleukin-1 of the action of eryth-ropoietin on erythroid precursors and its possible role in the pathogenesis of hypo-plastic anaemias. Br J Haematol 1987;67:11-17.
24. Jelkmann W, Pagel H, Wolff M, Fandrey J: Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 1992; 50:301-308.
25. Remick DG, Kunkel RG, Larrick JW, Kunkel SL: Acute in vivo effects of human recombi-nant tumor necrosis factor. Lab Invest 1987; 56:583-590.
26. Patton JS, Peters PM, McCabe J, Crase D, Hansen S, Chen AB, Liggitt D: Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-α in rodents. J Clin Invest 1987; 80:1587-1596.
27. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
28. Chiang CK, Ho TI, Hsu SP, Peng YS, Pai MF, Yang SY, Hung KY, Tsai TJ: Low-density lipoprotein cholesterol: association with mortality and hospitalization in hemodialysis patients. Blood Purif 2005;23:134-140.
29. Iseki K, Yamazato M, Tozawa M, Takishita S: Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002;61:1887-1893.
30. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808.
31. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC: Effects of statins in patients with chronic kidney disease: meta-analysis and meta-re-gression of randomised controlled trials. BMJ 2008;336:645-651.